• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinoxalines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinoxalines

Benzoaphenazine 12-Oxide (CAS No. 18636-87-8): A Comprehensive Overview

Benzoaphenazine 12-Oxide, with the chemical formula C??H?N?O?, is a significant compound in the field of pharmaceutical chemistry and biochemistry. Its CAS number, CAS No. 18636-87-8, uniquely identifies it in scientific literature and databases, facilitating accurate referencing and research. This compound has garnered attention due to its unique structural properties and potential biological activities, making it a subject of extensive study in both academic and industrial research settings.

The molecular structure of Benzoaphenazine 12-Oxide consists of a benzoaphenazine core substituted with an oxygen group at the 12-position. This structural feature contributes to its distinct chemical behavior and reactivity, which are of great interest to researchers exploring novel pharmacophores. The presence of the oxygen atom introduces polarity to the molecule, influencing its solubility, stability, and interactions with biological targets.

In recent years, Benzoaphenazine 12-Oxide has been studied for its potential applications in drug discovery and development. Its unique chemical scaffold suggests possible utility in modulating various biological pathways, particularly those involving oxidative stress and inflammation. Preliminary studies have indicated that this compound may exhibit antioxidant properties, which could be beneficial in the treatment of oxidative-related diseases such as neurodegenerative disorders and cardiovascular conditions.

One of the most compelling aspects of Benzoaphenazine 12-Oxide is its structural similarity to other bioactive molecules that have shown promise in clinical trials. This similarity has prompted researchers to investigate its potential as a lead compound for further derivatization and optimization. By leveraging computational chemistry and high-throughput screening techniques, scientists are exploring ways to enhance its potency, selectivity, and pharmacokinetic profiles.

The synthesis of Benzoaphenazine 12-Oxide is another area of active research. Researchers have developed several synthetic routes to produce this compound with high yield and purity. These methods often involve multi-step organic transformations, including cyclization reactions and oxidation processes, which highlight the compound's synthetic accessibility. The development of efficient synthetic protocols is crucial for enabling large-scale production and further exploration of its biological activities.

Evaluation of the pharmacological properties of Benzoaphenazine 12-Oxide has revealed intriguing findings. In vitro studies have demonstrated its ability to interact with specific enzymes and receptors, suggesting potential therapeutic effects. For instance, it has been observed to inhibit certain inflammatory pathways by modulating key signaling molecules. Additionally, its interaction with mitochondrial respiration has been explored, indicating a possible role in managing metabolic disorders.

The toxicological profile of Benzoaphenazine 12-Oxide is also a critical area of investigation. Comprehensive safety assessments have been conducted to evaluate its acute and chronic toxicity. These studies have provided valuable insights into its safety margins and potential side effects, which are essential for determining its suitability for clinical development. The results from these toxicological studies are being used to refine dosing regimens and formulation strategies.

The future directions for research on Benzoaphenazine 12-Oxide are multifaceted. One key focus is on understanding its mechanism of action at a molecular level. Advanced techniques such as crystallography and spectroscopy are being employed to elucidate how this compound interacts with biological targets. This detailed understanding will be instrumental in designing more effective derivatives with enhanced therapeutic properties.

Furthermore, preclinical studies are being planned to assess the efficacy of Benzoaphenazine 12-Oxide in animal models of human diseases. These studies will provide critical data on its pharmacodynamics and pharmacokinetics, paving the way for potential clinical trials. Collaborations between academic institutions and pharmaceutical companies are fostering these preclinical efforts, bringing together expertise in chemistry, biology, and medicine.

The regulatory aspects associated with the development of Benzoaphenazine 12-Oxide are also being addressed. Compliance with regulatory guidelines from agencies such as the FDA and EMA is essential for ensuring that any future drug candidates derived from this compound meet stringent safety and efficacy standards. Engaging with regulatory bodies early in the development process can help streamline approvals and accelerate market entry.

In conclusion, Benzophenazine 12-Oxide (CAS No. 18636-87-8) represents a promising compound with significant potential in pharmaceutical research. Its unique structure, combined with preliminary evidence of bioactivity, makes it an attractive candidate for further exploration. As research continues to uncover new insights into its properties and applications, this compound is poised to contribute valuable advancements in the treatment of various diseases.

• 6935-29-1(Quinoxaline, 1-oxide)
• 304-81-4(Phenazine, 5-oxide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)